Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 4 minute read Pharma Industry News Alamar Biosciences and DZNE partner to profile 23,000 samples in landmark neurodegeneration biomarker study Alamar Biosciences partners with DZNE to deploy its NULISAseq panels in the Rhineland Study, profiling 23,000 plasma samples for aging and dementia biomarker discovery. bySoujanya RaviJuly 29, 2025